Friday, 16 October 2026European Markets

TRIGANO Stock Over 9% Up So Far On Thursday

Loading stream...

(vianews) - shares of trigano (cac 40: tri.pa) rose 9.78% to €126.90 at 11:07 est on thursday, after three successive sessions in a row of losses. cac 40 is rising 0.97% to €7,471.53, after two consecutive sessions in a row of losses. this seems, so far, a somewhat positive trend exchanging session today.

about trigano

trigano s.a., together with its subsidiaries, engages in the design, manufacture, marketing, and sale of leisure vehicles for individuals and professionals in europe. it offers camping cars, caravans, motorhomes, trailers, and outdoor habitats. the company also provides mobiles homes, spare parts, and accessories, as well as leisure financing services. it offers its products through dealer networks and distributors, as well as through its online sales site, triganostore.com. trigano s.a. was founded in 1935 and is based in paris, france.

earnings per share

as for profitability, trigano has a trailing twelve months eps of €14.45.

pe ratio

trigano has a trailing twelve months price to earnings ratio of 8.78. meaning, the purchaser of the share is investing €8.78 for every euro of annual earnings.

volatility

trigano's last week, last month's, and last quarter's current intraday variation average was a negative 0.65%, a negative 0.01%, and a positive 1.11%.

trigano's highest amplitude of average volatility was 0.65% (last week), 1.07% (last month), and 1.11% (last quarter).

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, trigano's stock is considered to be overbought (>=80).

volume

today's last reported volume for trigano is 36786 which is 98.35% above its average volume of 18546.

more news about trigano (tri.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com